SDC2 and neoplasm: Overexpression of SDC2‐peptide in TASCs resulted in significantly lower tumour volume by Day 27 compared to tumours containing control‐transfected TASCs (Figure 4E) and lower metastatic scores in the lungs (Figure 4F).